StemCells' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Good day ladies and gentleman and thank you for standing by and welcome to the Fourth Quarter 2013 StemCells, Incorporated Earnings Conference Call.
Neuralstem And Brainstorm Cell Therapeutics: The Race To Treat ALS
Both companies have demonstrated an excellent safety profile and strong hints of efficacy, which is truly a "breakthrough" therapy for a very difficult, incurable disease.
Stemcells (STEM) Scheduled to Post Earnings on Wednesday
Stemcells will be releasing its earnings data on Wednesday, March 12th. Persons that are interested in participating in the company's earnings conference call can do so using this link .
StemCells Inc. To Participate At Investor Day In New York
StemCells, Inc. announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City.
StemCells Inc. Announces Webcast To Discuss Fourth Quarter And Full Year 2013 Financial Results
StemCells, Inc. , a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will ... (more)
Stemcells, Inc. And Advanced Cell Technology: The Race To Treat AMD
In my last two articles; " Advanced Cell Technology: A Balanced Perspective Of Risk and Reward " and " StemCells, Inc., And Neuralstem, Inc.: A Side-By-Side Analysis ", I first took a broad, balanced view of the investment risk and return profile of Advanced Cell Technology based on recent developments, and in my second article, I took an even ... (more)
StemCells Inc. Announces Completion Of The First Of Two Cohorts In...
StemCells, Inc. announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SCA product candidate for dry age-related macular degeneration .